• FirefoxInstall the new Firefox »
  •  Dow Up0.19% Nasdaq Up0.57%

    Fidelity Advisor Biotechnology C (FBTCX)

    25.18 Up 0.54(2.19%) Mar 27

    Profile as of Feb 27, 2015Get Profile for:
    Fidelity Advisor Biotechnology C
    Fidelity Advisor Series VII82 Devonshire StreetBoston, MA 02109
    Phone: 877-208-0098
    Fund Overview 
    Fund Family:Fidelity Investments
    Net Assets:2.84B
    Year-to-Date Return:11.13%
    Morningstar Rating:5 stars
    Fund Inception Date:Dec 27, 2000
    Morningstar Style Box 
    [View Category Definition]
    View Top Health Funds
    About the Morningstar Style Box
    Management Information 
    Rajiv Kaul
    Lead Manager since Oct 12, 2005
    Kaul is a portfolio manager with Fidelity Investments. Since joining Fidelity Investments in 1996, he has worked as a research analyst and portfolio manager. Kaul also manages another Fidelity fund. He is the recipient of the Kann Rasmusson Environment Award, the Dean's Summer Research Award and a Ford Undergraduate Fellowship.
    Investment Information 
    Min Initial Investment:2,500
    Min Initial Investment, IRA:500
    Min Initial Investment, AIP:2,500
    Min Subsequent Investment:N/A
    Min Subsequent Investment, IRA:N/A
    Min Subsequent Investment, AIP:100
    FBTCX can be purchased from 63 brokerages.

    Fund Summary 
    The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments. The fund is non-diversified.

    Fund Operations 
    Last Dividend : 0.00
    Last Cap Gain (Dec 11, 2014) : 0.00
    Annual Holdings Turnover (Mar 25, 2015) : 50.00%
    Average for Category:55.28%
    Fees & Expenses 
    ExpenseFBTCXCategory Avg
    Annual Report Expense Ratio (net):1.83%1.43%
    Prospectus Net Expense Ratio:1.83%N/A
    Prospectus Gross Expense Ratio:1.83%N/A
    Max 12b1 Fee:1.00%N/A
    Max Front End Sales Load:N/A5.28%
    Max Deferred Sales Load: 1.00%2.37%
    3 Yr Expense Projection*:576604
    5 Yr Expense Projection*:990926
    10 Yr Expense Projection*:2,1481,819
    * Per $10,000 invested